NATR

Business Context and Reporting Period

Company: Nature's Sunshine Products, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2002
Business Overview: The Company manufactures and markets nutritional and personal care products (herbal products, vitamins, minerals, and personal care items) sold globally through a direct-selling network of independent Distributors and Managers. Operations are headquartered in Provo, Utah, with significant international presence in Latin America, Asia Pacific, and other regions.

Key Financial Metrics (Year Ended Dec 31, 2002)

Margins: Operating margin declined to 3.9% in 2002 from 7.5% in 2001. Net profit margin fell to 2.4% from 5.2%.

Material Changes vs. Prior Period

• Revenue Decline: Consolidated sales decreased 6% primarily due to a 14% drop in international revenue. Specific declines occurred in South Korea (increased competition), Venezuela (political unrest and currency devaluation), and Brazil (import regulations).
• Profitability Compression: Operating income dropped 51% and Net Income dropped 58%. This was driven by lower sales volume and a $3.0 million impairment charge on investments in Cetalon Corporation.
• Expense Increases: Selling, General, and Administrative (SG&A) expenses rose to 34.0% of sales (from 30.3% in 2001) due to increased promotional programs and costs associated with the Synergy acquisition.
• Capital Structure: The Company entered a new $15.0 million operating line of credit, with $5.5 million drawn as of year-end. There is no long-term debt.
• Share Repurchases: The Company spent approximately $16.9 million repurchasing 1.5 million shares of common stock in 2002.

Guidance, Outlook, and Risks

• Outlook: Management anticipates a 2% price increase in the U.S. market effective April 1, 2003, to offset raw material costs. Price increases are also planned in international markets to counter currency devaluations. SG&A expenses as a percent of sales are expected to decrease in 2003 due to cost-control measures and a hiring freeze.
• Product Liability Risk: The Company faces significant risk regarding products containing ephedrine alkaloids and kava. Due to regulatory scrutiny, the Company cannot obtain product liability insurance for these items (approx. 2% of products). Premiums for insurable products increased 35% in 2002 with reduced coverage. The Company has accrued a liability for potential claims but notes that uninsured claims could materially impact results.
• International Risks: Continued exposure to foreign currency fluctuations, political instability (specifically Venezuela and Brazil), and import/export controls.
• Accounting Changes: The Company adopted SFAS No. 142 (Goodwill) and SFAS No. 144 (Impairment of Long-Lived Assets) in 2002, though these did not have a material impact on reported results.

Investor Verification Checklist

• International Exposure: Verify the stability of operations in Venezuela and Brazil given the cited political unrest and regulatory changes.
• Insurance Coverage: Assess the adequacy of the accrued liability for uninsured product liability claims related to ephedrine and kava products.
• Revenue Quality: Confirm the sustainability of the direct sales force (509,000 active distributors) and the impact of the 30% annual renewal rate on future revenue.
• Liquidity: Monitor the utilization of the $15.0 million line of credit and the Company's ability to service debt if operating cash flows remain depressed.
• Investment Impairments: Review the status of remaining long-term investments to ensure no further impairments similar to the Cetalon write-down are necessary.